Arthrogryposis
14 treatments and conditions followed through the public trial records. Not medical advice.How a status is set
Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| ALK-inhibitor or RET-inhibitor + BNT116 for arthrogryposis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| anti-HER3 antibody conjugated to topoisomerase I inhibitor + BNT116 for arthrogryposis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BNT116 for arthrogryposis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BNT116 + BNT316 for arthrogryposis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BNT116 + CEMIPLIMAB for arthrogryposis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BNT116 + CEMIPLIMAB + Carboplatin + Paclitaxel for arthrogryposis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BNT116 + DOCETAXEL for arthrogryposis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BNT116 + OSIMERTINIB for arthrogryposis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BNT116 + Pumitamig for arthrogryposis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BNT116 + Tambotatug Pelitecan for arthrogryposis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BNT326 for arthrogryposis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BNT326 + ITRACONAZOLE for arthrogryposis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BNT326 + Paroxetine for arthrogryposis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BNT326 + Pumitamig for arthrogryposis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |